Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-02-19
2000-02-08
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31445
Patent
active
060228776
ABSTRACT:
The present invention is directed to the use of (+)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidine methanol in treating Depressive Disorders and Bipolar Disorders.
REFERENCES:
patent: 4762842 (1988-08-01), Cohen et al.
patent: 4783471 (1988-11-01), Carr et al.
patent: 4877798 (1989-10-01), Sorensen
patent: 4902691 (1990-02-01), Cohen et al.
patent: 4908369 (1990-03-01), Schechter et al.
patent: 4912117 (1990-03-01), Carr et al.
patent: 5021428 (1991-06-01), Carr et al.
patent: 5064838 (1991-11-01), Carr et al.
patent: 5106855 (1992-04-01), McLees
patent: 5134149 (1992-07-01), Carr et al.
patent: 5169096 (1992-12-01), Carr et al.
patent: 5561144 (1996-10-01), Carr et al.
patent: 5618824 (1997-04-01), Schmidt et al.
patent: 5643784 (1997-07-01), Bogeso et al.
patent: 5700812 (1997-12-01), Carr et al.
patent: 5700813 (1997-12-01), Carr et al.
patent: 5721249 (1998-02-01), Carr et al.
Kehne, John H. et al., The Jrnl of Pharmacology and Experimental Therapeutics, vol. 277, No. 2, pp 968-981, 1996.
Adis LMS Drug Alerts Abstract of Kennedy et al., Int. Clin. Psychopharmacol. 6 (Suppl. 1):54-72, Jul. 1991.
Anxiolytic Serotonin Antagonist: Drugs of the Future, vol. 14, No. 5 (pp. 489-490) (1989).
Psychopharmacology, vol. 96 (pp. 395-399) (1988).
Acta Psychiatr Scand, vol. 83 (pp. 244-248) (1991).
Drug Development Research, vol. 8 (pp. 205-211) (1986).
Sleep, vol. 16, No. 7 (pp. 647-654) (1993).
Journal of Clinical Psychopharmacology, vol. 13, No. 6 (pp. 409-414) (1993).
A. Sluzewska, et al., Behavioral Pharmacol. 5, Suppl. 1, p 86 (1994).
Willner, Pharmac. Ther. vol. 45, pp 425-455 (1990).
Willner, et al., Psychopharmacology 93, pp 358-364 (1987).
J.-L. Moreau et al., Behavioural Pharmacology, 5, pp 344-350 (1994).
Willner, TIPS. vol. 56, No. 25, pp 131-136 (1991).
C.J. Schmidt, et al., Life Sciences, vol. 56, No. 25, pp 2209-2222 (1995).
S.Kasper et al., Human Psychopharmacology, vol. 9, pp 1-12 (1994).
C.J. Schmidt et al., EP Journal of Pharmacology, vol. 273, No. 1/2, pp 273-279 (1995).
J.A. Den Boer et al., Human Psychopharmacology, vol. 10, pp S173-S183, (1995).
C.J. Schmidt et al., Life Sciences, vol. 56, No. 25 (1995).
G.J. Marek et al., European Journal of Pharmacology, vol. 259, No. 1, pp 137-141 (1994).
Henley III Raymond
Hoechst Marion Roussel Inc.
Moon Carolyn D.
LandOfFree
Use of (+)-.alpha.-(2,3-dimethoxyphenyl-1-[2-(4-fluorophenyl)eth does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of (+)-.alpha.-(2,3-dimethoxyphenyl-1-[2-(4-fluorophenyl)eth, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of (+)-.alpha.-(2,3-dimethoxyphenyl-1-[2-(4-fluorophenyl)eth will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1681658